Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 10Recruiting 5Completed 5Terminated 1Suspended 1Not yet recruiting 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma 1HTLV-I Infections 1

Interventions

Specimen Handling 21Biopsy 15Magnetic Resonance Spectroscopy 12Cyclophosphamide 4decitabine and cedazuridine drug combination 3X-Rays 3Vincristine 3Nivolumab 3Doxorubicin 3venetoclax 2trastuzumab deruxtecan 2olaparib 2iadademstat 2Taxes 2Surgical Procedures, Operative 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Prednisone 2Ipilimumab 2Immunoglobulin G 2Disulfides 2Cetuximab 2CTLA-4 Antigen 2Azacitidine 2Actinium 2(225)Ac-DOTA-c(RGDyK) 2sargramostim 1relatlimab 1prednylidene 1neratinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × NIH × deltacortene × Clear all
NCT04301076 2026-05-13

Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)

National Cancer Institute (NCI)

Phase 1 Suspended
30 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, HTLV-I Infections, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡